Novo Nordisk A/S (NOVO-B.CO)
Health Care · Europe (developed)
Price, dispersion, largest decline and relative strength for Novo Nordisk A/S — computed nightly and open to read. Whatever assessment goes beyond that, hentschel.ai computes alongside your portfolio.
Measured metrics
Every value below describes what has already happened. They are computed nightly from price and reported data and contain no assessment and no expectation.
Annualised dispersion of the daily closing prices across the trailing window.
Lowest point measured against the preceding high within the same window.
Twelve-month price return minus that of a global equity benchmark. Not currency-adjusted.
The same calculation over three months.
Distributions over the past twelve months relative to the current price.
Deviation of the last reported earnings per share from the analyst estimate.
Computed on 2026-10-02. Metrics are refreshed nightly.
What hentschel.ai also computes for Novo Nordisk A/S
We compute more for this security every night than is shown here. The judgement-forming part is deliberately not published: it only means something alongside a specific portfolio and a specific risk tolerance, and detached from those it would mislead rather than help.
- Valuation in context
Where the security stands against its sector peers and against its own valuation history.
- Priced-in expectation
The earnings growth the current price implies — reverse-engineered from the price rather than forecast.
- Quality and franchise profile
Margins, capital intensity, cash conversion and balance-sheet soundness, condensed into two separate axes.
- Analyst revisions
Where earnings estimates are moving over 30 and 90 days, and how broadly the revisions are carried.
- Technical and fundamental picture
Both layers brought together and put in context — including where they contradict each other.
- Fit with your portfolio
Overlap with existing positions, plus sector, region, currency and theme exposure after an addition.
- Allocation and backtest
A concrete weighting proposal and a backtest of how that change would have played out historically.
This page shows measurements, not an assessment. hentschel.ai is a research and explanation tool, not investment advice — inside the product the decision stays yours too.
Analyse Novo Nordisk A/S with hentschel.ai now
Start for free and get your first AI-powered analysis in under two minutes.
Private beta: signing up currently requires an invite code.
More from Health Care
All analyses →Live price data from third parties, without warranty as to accuracy, completeness or timeliness. Metrics and scores are computed by us and the text is generated by an AI model — these layers can be wrong too. This page does not constitute investment advice. You make your own investment decisions.